Atea Q2 FY26 net loss narrows 11.4% to $32.93 million

AVIR•2026-08-12

Cash position and pipeline milestones

Cash and investments slid to $219.47 million at June 30 from $301.83 million at Dec. 31.

Phase 3 C-BEYOND met primary and secondary endpoints; C-FORWARD topline results are expected early Q1 2027, with an FDA NDA submission targeted for Q2 2027.

Q2 loss and expenses improve year over year

Atea Pharmaceuticals posted a Q2 net loss of $32.93 million, narrowing 11.38% year over year; loss per share improved to $0.41.

Operating loss narrowed 15.11% to $35.1 million, with research and development expense down 12.78% to $28.15 million.

General and administrative expense fell 23.38% to $6.95 million; interest income dropped 50.12% to $2.19 million on lower investment balances.

Atea Q2 FY26 net loss narrows 11.4% to $32.93 million

Cash position and pipeline milestones

Q2 loss and expenses improve year over year

Related News

Omega International Q2 FY26 net loss widens to $49,833; revenue rises 450% to $1.05 million

American Exceptionalism Acquisition net income rises to $2.82 million in Q2 FY26

OS Therapies prices up to $10 million senior secured convertible note private placement

Pelican Acquisition II units begin separate trading of shares and rights Aug. 12

Park Dental Partners Q2 FY26 net income drops 47.5% to $1.3 million; revenue rises 5.1% to $66.2 million